AbbVie rises after Phase 3 SKYRIZI data show efficacy in Crohn's disease

What happened

AbbVie rose 1.5% on October 9, 2026, after Phase 3 AFFIRM results showed subcutaneous SKYRIZI delivered superior clinical and endoscopic responses in Crohn’s disease. AbbVie (ABBV) said the results, reported by PRNewsWire, also included open-label extension analyses that indicated sustained endoscopic outcomes over time. The announcement referenced data on RINVOQ in inflammatory bowel disease and was the main development around the company that day.

How big was the move

The stock closed at $276.47, having risen 1.5% on the day and risen 5.2% over the last five sessions. Trading volume was 0.9 times its 20-day average and the move measured 1.2 times a typical daily move for this stock. The S&P 500 rose 0.6% on the day and rose 1.1% over five sessions; the Healthcare sector median rose 1.4% on the day, so the stock was 0.1 percentage points better than the sector median.

Taken together, those figures point to an ordinary session for the stock rather than an unusual volatility spike. The stock has a beta of 0.07, which means the stock tends to move less than the market, and the size of the move fit that lower sensitivity.

The technical picture

The stock was 4.2% above its 20-day moving average and 6.8% above its 50-day moving average, and 18.8% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had been above its 200-day average for 78 consecutive trading days. The Relative Strength Index (14 days) was 71 (above 70, a level often called overbought) and the share price was 0.4% below the 52-week high.

Shorter-term momentum has been positive. The stock rose 8.4% over one month and rose 11.5% over three months. Over one year it rose 19.6%, which was 3.9 percentage points ahead of the S&P 500 over the same period. Volatility was lower than historical norms, with 20% annualized over 60 days, lower than 68% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, the company reported revenue of $64.39 billion, which grew 10.4% from a year earlier and followed revenue growth of 9.5% one quarter earlier. Diluted earnings per share were $3.55, and earnings per share grew 68.1% from a year earlier. The stock’s gross margin was 71.5% (a year earlier: 70.9%) and operating margin was 29.3% (a year earlier: 18.8%). Free-cash-flow margin was 30.6% and return on invested capital was 13.5%.

The balance sheet showed net debt of 3.0 times EBITDA. Valuation measures included 77.9 times trailing earnings and 19.7 times expected earnings on a price to forward earnings basis. Free-cash-flow yield was 4.2%. The price to trailing earnings was higher than 71% of its own readings over the past five years (five-year median: 48.6 times earnings).

Taken together, the company delivered solid margin expansion and cash generation, while the stock traded at a premium on a trailing earnings basis relative to its own recent history. That contrast is reflected in high Quality and Stability scores from PromtFinance alongside more neutral Value and Growth scores.

Earnings and analyst expectations

AbbVie’s next report was scheduled for October 30, 2026. The last report, on July 31, 2026, recorded earnings per share of $3.65 against $3.61 expected, 1.1% above estimates. The company had posted six consecutive quarters beating estimates and an average surprise over the last four reports of 2.7% above estimates. Typical two-day reactions after recent reports saw the stock rose 0.8%.

Analysts’ consensus price target was $287.08, 3.8% above the closing price on October 9, 2026. Forty-three analysts had a rating on the stock and 72% of those ratings were Buy; the consensus rating was Buy. PromtFinance scores ranked the company within the sector as Value 62 (Neutral), Growth 60 (Neutral), Quality 96 (Exceptional), Momentum 81 (Strong), Revisions 46 (Neutral) and Stability 95 (Exceptional).

What to watch

• October 30, 2026: next scheduled earnings report
• The Phase 3 AFFIRM program outcomes and any subsequent peer-reviewed publications or conference presentations
• Performance of SKYRIZI in open-label extension analyses and any subgroup data tied to complex disease characteristics
• Any updates or data releases related to RINVOQ in inflammatory bowel disease
• Changes in consensus price target from $287.08 or shifts among the 43 analysts